The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

The global disposable insulin-delivery device market is projected to experience robust growth over the next decade, according to recent industry insights. Valued at USD 14,585.6 million in 2022, the ...

Aussies have been warned to think before they jab, with more counterfeit Ozempic-labelled products seized at the border.

Learn more about whether Jazz Pharmaceuticals plc or Novo Nordisk A/S is a better investment based on AAII's A+ Investor ...

In the realm of investing, finding value in mega-cap stocks can often seem like searching for a needle in a haystack. Nvidia ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...

The Business Research Company Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout. LONDON, GREATER ...

Novo Nordisk’s once‐weekly injectable, Ozempic (semaglutide), originally developed for type 2 diabetes, has increasingly ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...